Technology | May 19, 2011

FDA Expands Indication for CrossBoss, Stingray to Treat CTOs

May 19, 2011 - BridgePoint Medical Inc. has announced that they have received clearance of an expanded indication for the CrossBoss Catheter and Stingray System from the U.S. Food and Drug Administration (FDA). The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention. CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer – and prevent blood circulation to critical areas of the heart. This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated. William Lombardi, M.D., of St. Joseph's Hospital in Bellingham, Wash., and a leading enroller in the clinical trial states, "The BridgePoint system is the first set of devices designed specifically for treating coronary CTOs that has shown real improvements in safety, procedural efficiency, and clinical success rates. The clinical trial has proven that these arteries can be opened effectively with these products and now with the expanded indication from the FDA there will be a new level of awareness among physicians and patients." BridgePoint's ability to commercialize its CrossBoss Catheter and Stingray System will be greatly expanded with this new level of indication. BridgePoint is the first interventional device company to be granted this specific type of approval for both crossing and re-entry technologies to be used in the treatment of coronary CTOs. For more information: www.bridgepointmedical.com

Related Content

BioCardia Initiates Commercial Release of Avance Steerable Introducer
News | Catheters | October 23, 2019
BioCardia announced the U.S. commercial availability of its Avance Bi-Directional Steerable Introducer Sheath for...
Cook Medical Launches 2.6 Fr CXI Support Catheter
Technology | Catheters | August 23, 2019
August 23, 2019 — Cook Medical recently released the second generation of the 2.6 Fr CXI...
Biocardia Receives FDA Clearance for Avance Steerable Introducer Family
Technology | Catheters | May 16, 2019
BioCardia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Avance steerable introducer...
Navitian Coronary Microcatheter Receives CE Mark Approval
News | Catheters | February 21, 2019
Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The device was approved to...
First U.S. Patients Treated With OrbusNeich Teleport Microcatheter
News | Catheters | January 31, 2019
Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich...
Merit Medical Acquires Assets of Vascular Insights LLC
News | Catheters | December 18, 2018
Merit Medical Systems Inc. announced that it has acquired substantially all of the assets of Vascular Insights LLC,...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
Overlay Init